TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

20251 citationsJournal Article

Authors

Pascal Hammel · Hôpital Paul-Brousse

Jean‐Philippe Metges · Hôpital Maison Blanche

Teresa Macarulla · Vall d'Hebron Hospital Universitari

Rocio García‐Carbonero · Universidad Complutense de Madrid

Olivier Bouché · Centre Hospitalier Universitaire de Reims

Fabienne Portales · Institut de Recherche en Cancérologie de Montpellier

Roberto Pazo-Cid

Abstract

The addition of eryaspase to chemotherapy did not improve OS, PFS, or ORR. AEs were generally consistent with previous reports of chemotherapy. These results do not support additional development of eryaspase in PDAC.

Topics & Keywords

Protein Kinase Regulation and GTPase Signaling Proteoglycans and glycosaminoglycans research Cell death mechanisms and regulation

Publication Details

Published in: Journal of Clinical Oncology

Volume 43, Issue 35, pp. 3714-3727

DOI: 10.1200/jco-25-00872

Field-Weighted Citation Impact: 0.81

Command Palette

TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

Authors

Abstract

Topics & Keywords

Publication Details